PhD/MPhil/MD Pharmacology in Liverpool United Kingdom | University of Liverpool

The Department of Molecular and Clinical Pharmacology offers outstanding prospects for fundamental and applied research across drug safety science, immuno-pharmacology, precision medicine, nanomedicine, and HIV studies. Recognized as one of the UK's top research institutions, the department houses both the MRC-funded Centre for Drug Safety Science and the Wolfson Centre for Personalized Medicine.

Our cutting-edge research infrastructure receives support from prestigious funders including the MRC, BBSRC, Wellcome Trust, NIHR, Wolfson Foundation, and EU programs.

We concentrate on investigations that illuminate disease mechanisms, develop therapeutic approaches, and establish the scientific foundations of medication safety. This work ultimately aims to transform laboratory discoveries into clinical applications that benefit patients, communities, and healthcare systems.

Our specialized research areas include:

Drug Safety Science - Conducting essential clinical and basic research on adverse drug reactions to enhance the safety profile of existing and emerging medications
Precision Medicine - Investigating individual variations in drug responses to enable tailored treatments
Immuno-pharmacology - Exploring drug-immune system interactions to uncover new therapeutic targets
Infectious Disease Pharmacology - Studying response variability to HIV, tuberculosis, and hepatitis treatments at molecular levels
Nanomedicines - Developing nanoparticle applications for infectious disease management
Neuropharmacology - Researching neurological disorder origins and pioneering novel therapies
Drug Safety Science - As adverse reactions pose major challenges, our MRC-designated Center leads European research into reaction mechanisms and genetic predispositions, aiming to improve diagnosis and clinical management
Personalised Medicine - Through the Wolfson Centre, we're transforming disease treatment by identifying genetic markers that predict drug responses in conditions like cardiovascular disease, asthma, and epilepsy. Our interdisciplinary team bridges laboratory breakthroughs with clinical implementation for enhanced patient outcomes.